{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:58:20Z","timestamp":1790668700518,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>By 2021, regulatory agencies had approved two glucagon-like peptide-1 receptor agonists (GLP-1RAs), semaglutide and liraglutide, for the treatment of type 2 diabetes and obesity. Since then, concerns have emerged about whether adverse events (AEs) differ by GLP-1RA or indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>We analyzed the Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2021\u20132025) to compare adverse events associated with semaglutide and liraglutide indications. Comparisons with metformin and orlistat helped distinguish drug-related signals from disease-related signals. We defined safety signals by a positive reporting odds ratio and at least one other positive disproportionality metric.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 8,213,105 FAERS reports, 33,259 met the inclusion criteria. Semaglutide generated more reports for type 2 diabetes than for obesity (13,168 vs. 5,444), and liraglutide showed a similar pattern (1,201 vs. 837). GLP-1RAs exhibited gastrointestinal AEs. Semaglutide showed signals for slowed gastrointestinal motility across both indications, particularly impaired gastric emptying, in both type 2 diabetes and obesity reports (ROR = 8.35, 95% CI = 1.16\u201359.97 and ROR = 4.01, 95% CI = 2.12\u20137.58, respectively). Liraglutide demonstrated signals for more severe gastrointestinal AEs, including abdominal distention in type 2 diabetes (ROR = 1.46, 95% CI = 1.12\u20131.91) and pancreatitis in obesity (ROR = 2.90, 95% CI = 1.91\u20134.39) reports. Additional notable safety signals included optic ischemic neuropathy with semaglutide (ROR = 4.42, 95% CI = 1.41\u201313.87) and psychiatric AEs, including suicidal ideation (ROR = 5.98, 95% CI = 1.24\u201324.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified robust signals for GLP-1RAs, including impaired gastric emptying, ileus, and ischemic optic neuropathy. Additionally, we identified signals for suicidal ideation. Future studies are needed to evaluate for causal relationships.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1936967","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:44:10Z","timestamp":1790667850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Samuel A.","family":"Fisch","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan J.","family":"Neugut","sequence":"additional","affiliation":[{"name":"Department of Statistics, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cornet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Quigee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred I.","family":"Neugut","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University","place":["New York, NY, United States"]},{"name":"Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Freedberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University","place":["New York, NY, United States"]},{"name":"Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like Peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff","year":"2005","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"B5","volume-title":"Approval Letter for NDA 022341","year":"2010"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1032199","DOI":"10.3389\/fendo.2022.1032199","article-title":"Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B9","volume-title":"EMA Statement on Ongoing Review of GLP-1 Receptor Agonists","year":"2023"},{"key":"B6","volume-title":"FDA Begins Real-Time Reporting of Adverse Event Data","year":"2025"},{"key":"B10","volume-title":"Update on Fda\u2019s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity","year":"2026"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jama.2024.10333","article-title":"Poll: roughly 12% of US adults have used a GLP-1 drug, Even if unaffordable","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1186\/s40001-025-02836-5","article-title":"Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study","volume":"30","author":"Hep\u015fen","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000552104","article-title":"Real-world comparison of short-term adverse events, treatment persistence, and efficacy of semaglutide and tirzepatide: a nationwide multicenter study","author":"Hep\u015fen","year":"2026","journal-title":"Obes. Facts"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e103234","DOI":"10.7759\/cureus.103234","article-title":"The benefits and risks of glucagon-like Peptide-1 receptor agonists on ocular diseases: a narrative review","volume":"18","author":"Huang","year":"2026","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA adverse event reporting system database","volume":"68","author":"Lu","year":"2025","journal-title":"Eur. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/OP-26-00485","article-title":"GLP-1 agonists are associated with a significant reduction in breast cancer incidence in women","volume":"22","author":"McDonald","year":"2026","journal-title":"JCO Oncol. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.3390\/diagnostics14242829","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagn. (Basel)"},{"key":"B24","volume-title":"FAERS: R Interface for FDA Adverse Event Reporting System","author":"Peng","year":"2026"},{"key":"B25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B26","volume-title":"R: A Language and Environment for Statistical Computing","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","first-page":"20420188251406456","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2526321","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1\u2013Based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like Peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2024.0046","article-title":"GLP-1 receptor agonists and gastrointestinal adverse events","volume":"331","author":"Suissa","year":"2024","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7326\/M24-0329","article-title":"Glucagon-like Peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes","volume":"177","author":"Tang","year":"2024","journal-title":"Ann. Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am. J. Manag. Care"},{"key":"B37","volume-title":"NDA 206321 Approval Letter for Saxenda (liraglutide [rDNA origin] injection), 3 mg","year":"2014"},{"key":"B38","volume-title":"Approval Letter for NDA 209637 (Ozempic)","year":"2017"},{"key":"B39","volume-title":"Approval Letter for NDA 215256 (Wegovy)","year":"2021"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: a systematic review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","article-title":"Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study","volume":"15","author":"Zhou","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1936967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:44:13Z","timestamp":1790667853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1936967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":42,"alternative-id":["10.3389\/fphar.2026.1936967"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1936967","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1936967"}}